论文部分内容阅读
作者对104例涎腺恶性肿瘤术后采用化疗患者,分长期间断化疗(长期化疗)组和单纯手术切除或术后辅助化疗(传统治疗)组,进行3年～14年随访观察。结果发现3年生存率两组均较高(84.8％及82.8％),而5年生存率长期化疗组较传统治疗组高14.7％,10年生存率较传统治疗组高22.2％。因此可以看出术后长期间断化疗可以提高涎腺恶性肿瘤患者的远期生存率。
The authors conducted 104 patients with malignant tumors of the parotid gland after surgery using chemotherapy, divided into long-term intermittent chemotherapy (long-term chemotherapy) group and surgery alone or postoperative adjuvant chemotherapy (traditional treatment) group, 3 to 14 years of follow-up observation. The results showed that the 3-year survival rate was higher in both groups (84.8% and 82.8%), and the 5-year survival rate in the long-term chemotherapy group was 14.7% higher than that in the traditional treatment group, and the 10-year survival rate was 22.2% higher than that in the traditional treatment group. Therefore, it can be seen that postoperative long-term intermittent chemotherapy can improve the long-term survival rate of patients with parotid gland cancer.